Novo Nordisk A/S, of Bagsværd, Denmark, said a securities lawsuit has been filed in Denmark against the company by a number of shareholders who are claiming DKK11.785 billion (US$1.75 billion) based on their trading and holding of shares in Novo Nordisk during the period of Feb. 3, 2015, to Feb. 2, 2017. It alleges that the company made misleading statements and did not make appropriate disclosures regarding its sales of insulin products in the U.S. The lawsuit, the company said, appears to contain broadly similar allegations to those of the previously announced securities class-action lawsuit filed in the U.S. in 2017 on behalf of all purchasers of Novo Nordisk American depository receipts. Novo Nordisk said it disagrees with the allegations and is prepared to defend the company in this matter.

No Comments